# US 2001/0025038 A1 · Method of reducing craving in mammals

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0025038 A1
- Document ID: US20010025038A1
- Status: Published application
- Kind: A1
- Application number: 09/846,170
- Filed: 2001-05-01
- Published: 2001-09-27
- Earliest claimed: 1997-10-28
- Inventors: Vicki L. Coffin; Paul W. Glue
- Web page: https://patentgrep.com/patent/US20010025038A1

## CPC

- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A method of reducing cravings in a mammal to food or an addictive substance is disclosed. The method comprises administering to the mammal an effective amount of a D1/D5 antagonist or a D1/D5 partial agonist alone or in combination with other specified CNS compounds.

## Claims

### Claim 1

A method for reducing cravings to food or an addictive substance in a mammal comprising administering to the mammal an anti-craving effective amount of a D1/D5 antagonist, a D1/D5 partial agonist or mixtures thereof.

### Claim 2 (depends on 1)

The method of claim 1 wherein the D1/D5 antagonist or D1/D5 partial agonist is administered at a daily dosage range of about 0.01 to about 500 mg/kg.

### Claim 3 (depends on 2)

The method of claim 2 wherein the D1/D5 antagonist is administered at a daily dosage range of about 1 to about 150 mg/kg.

### Claim 4 (depends on 2)

The method of claim 2 wherein the addictive substance is cocaine, amphetamine, nicotine, opiates, tobacco or alcohol.

### Claim 5 (depends on 4)

The method of claim 4 wherein the D1/D5 antagonist is selected from the class consisting of SCH39166, SCH23390, BTS-73-947, NNC-22-0010, JHS-271, JHS-198, JHS-136 and A69024, and the D1/D5 partial agonist is SKF 38393.

### Claim 6 (depends on 5)

The method of claim 5 wherein the D1/D5 antagonist is SCH 39166.

### Claim 7 (depends on 6)

The method of claim 6 wherein the substance craved is food.

### Claim 8 (depends on 7)

The method of claim 7 further comprising the administration of a compound selected from the class consisting of sibutramine, fluoxitine, fenfluramine and analogs, amphetamine and analogs, phenteramine, diethylproprion and mazindol.

### Claim 9 (depends on 6)

The method of claim 6 wherein the substance craved is nicotine.

### Claim 10 (depends on 9)

The method of claim 9 further comprising the administration of a compound selected from the class consisting of buspirone and buproprion.

### Claim 11 (depends on 6)

The method of claim 6 wherein the substance craved is alcohol.

### Claim 12 (depends on 11)

The method of claim 11 further comprising the administration of a compound selected from the class consisting of disulfiram, acamprosate and naltrexone.

### Claim 13

A method for reducing cravings to food or an addictive substance in a mammal comprising administering to the mammal an anti-craving effective amount of a compound selected from a D1/D5 antagonist, a D1/D5 partial agonist and mixtures thereof, and a compound selected from the class consisting of:
A. anti-obesity compounds;
B. serotonin receptor agonists and antagonists;
C. antipsychotics/anxiolytics;
D. antidepressants;
E. dopaminergic agonists;
F. anticonvulsants/mood stimulants;
G. cocaine-like agonists;
H. cocaine catalytic antibodies; and
I. alcohol antagonist drugs.

### Claim 14 (depends on 13)

The method of claim 13 wherein the D1/D5 antagonist is selected from the class consisting of SCH39166, SCH23390, BTS-73-947, NNC-22-0010, JHS-271, JHS-198, JHS-136 and A-69024.

### Claim 15 (depends on 14)

The method of claim 14 wherein the D1/D5 antagonist is SCH39166.

### Claim 16

A method for reducing food cravings in a mammal comprising administering to the mammal an anti-craving effective amount of SCH 39166.

### Claim 17

A method for reducing nicotine cravings in a mammal comprising administering to the mammal an anti-craving effective amount of SCH 39166.

### Claim 18

A method for reducing alcohol cravings in a mammal comprising administering to the mammal an anti-craving effective amount of SCH 39166

### Claim 19

A kit to reduce cravings to food or an addictive substance comprising a compound selected from the class consisting of a D1/D5 antagonist, a D1/D5partial agonist and mixtures thereof in combination with one or more compounds selected from the class consisting of:
A. anti-obesity compounds;
B. serotonin receptor agonists and antagonists;
C. antipsychotics/anxiolytics;
D. antidepressants;
E. dopaminergic agonists;
F. anticonvulsants/mood stimulants;
G. cocaine-like agonists;
H. cocaine catalytic antibodies; and
I. alcohol antagonist drugs.

### Claim 20 (depends on 19)

The kit of claim 19 wherein the D1/D5 antagonist is SCH39166.
